In this phase 3 trial , treatment-naive patients from outpatient clinics in North America were randomly assigned by computer-generated allocation sequence with a block size of four in a 1:1 ratio to receive EVG/COBI/FTC / TDF or EFV/FTC/TDF , once daily , plus matching placebo .
